Magnetic Ventures

Project Eaden engages in the development and licensing of technologies for the production of sustainable food and meat alternatives.

Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs.

Transition Bio provides condensate technology for drug discovery and diagnostics. The company focuses on the discovery, analysis, and modulation of biological condensates, propelled by a differentiated technological capability that generates expansive drug development opportunities in a hypothesis-free manner.

Spotlight Therapeutics is a developer of gene editing therapeutics intended to edit specific cell populations directly in the body. The company's therapeutics are used to create next-generation programmable nucleases that can selectively target and edit cells, enabling physicians to treat their patient in an enhanced way.

Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.

AppliedVR offers virtual reality-based treatments that address the complexity of chronic pain. The company's mission is to empower patients with the tools to live life, beyond chronic pain. Rooted in cognitive behavioral therapy and mindfulness, AppliedVR’s EaseVRx is the first VR-based prescription therapeutic to receive Breakthrough Device Designation by the FDA. Offering a comprehensive approach that encompasses the biological, psychological and social factors that influence how people experience chronic pain, EaseVRx enables patients to change the way they process pain and develop new, positive habits and coping skills that improve quality of life. Patients can easily self-administer EaseVRx in the comfort of their own homes, at any time, without restrictions tied to a healthcare professional’s schedule — advancing remote care as well as quality, equity and efficiency in chronic pain management.

ConsejoSano offers multicultural engagement and navigation solutions for health plans, providers, states to help guide culturally diverse populations through the complexities of the health care system and drive improved performance, outcomes and satisfaction.

Resilience is a biopharmaceutical manufacturing and technology company based in La Jolla, California, established in 2020. It aims to enhance access to complex medicines and safeguard biopharmaceutical supply chains. The company specializes in end-to-end manufacturing and development solutions across various therapeutic modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. Resilience provides customized manufacturing capabilities that cater to the diverse needs of biopharmaceuticals at all stages of the drug development process, from pre-clinical development to commercial supply. With a focus on developing new manufacturing technologies, Resilience ensures high-quality and regulatory-compliant processes for complex and novel medicines.

Emme is a healthcare technology company with a mission to put women's health in women's hands, starting with birth control. Their first product, the Emme Smart Case and app, is an integrated technology-enabled solution designed to safeguard the birth control experience and help reduce the rate of missed pills. The pill forever changed women's health in 1960—Emme is making it compatible with the 21st century. For more information, visit https://www.emme.com.

Amagma Therapeutics is a biotechnology company that specializes in the discovery and development of antibody therapeutics against inflammatory diseases. Its technology overactive extracellular proteases trigger tissue damage that can sustain broad inflammatory responses. The company was founded in 2019 and headquartered in Waltham, Massachusetts.

Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis. The company was founded in 2019 and is based in New York.